PL361307A1 - Peptydy pochodzące od kazeiny i ich zastosowanie w leczeniu - Google Patents

Peptydy pochodzące od kazeiny i ich zastosowanie w leczeniu

Info

Publication number: PL361307A1
Authority: PL; Poland
Prior art keywords: peptides; casein; stimulating; therapy; derived peptides
Prior art date: 2000-03-01

Application number

PL36130701A

Other languages

English (en)

Inventor

Zvi Sidelman

Original Assignee

Chay 13 Medical Research Group N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-01

Filing date

2001-03-01

Publication date

2004-10-04

2001-03-01 Application filed by Chay 13 Medical Research Group N.V. filed Critical Chay 13 Medical Research Group N.V.

2004-10-04 Publication of PL361307A1 publication Critical patent/PL361307A1/pl

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
239000005018 casein Substances 0.000 title abstract 3
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title abstract 3
235000021240 caseins Nutrition 0.000 title abstract 3
238000002560 therapeutic procedure Methods 0.000 title 1
230000004936 stimulating effect Effects 0.000 abstract 3
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
210000000601 blood cell Anatomy 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
208000014951 hematologic disease Diseases 0.000 abstract 1
230000011132 hemopoiesis Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
235000013336 milk Nutrition 0.000 abstract 1
239000008267 milk Substances 0.000 abstract 1
210000004080 milk Anatomy 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Marine Sciences & Fisheries (AREA)
Biophysics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

PL36130701A 2000-03-01 2001-03-01 Peptydy pochodzące od kazeiny i ich zastosowanie w leczeniu PL361307A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL13483000A IL134830A0 (en)	2000-03-01	2000-03-01	Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them

Publications (1)

Publication Number	Publication Date
PL361307A1 true PL361307A1 (pl)	2004-10-04

Family

ID=11073892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL36130701A PL361307A1 (pl)	2000-03-01	2001-03-01	Peptydy pochodzące od kazeiny i ich zastosowanie w leczeniu

Country Status (21)

Country	Link
US (6)	US20020147144A1 (pl)
EP (1)	EP1261360B1 (pl)
JP (1)	JP2003528827A (pl)
KR (1)	KR20030025907A (pl)
CN (1)	CN1427725A (pl)
AT (1)	ATE451929T1 (pl)
AU (1)	AU782662B2 (pl)
BR (1)	BR0109027A (pl)
CA (1)	CA2401550A1 (pl)
CZ (1)	CZ20022915A3 (pl)
DE (1)	DE60140794D1 (pl)
DK (1)	DK1261360T3 (pl)
EA (3)	EA007217B1 (pl)
HU (1)	HUP0301003A3 (pl)
IL (2)	IL134830A0 (pl)
MX (1)	MXPA02008569A (pl)
NO (1)	NO20024157L (pl)
NZ (1)	NZ521016A (pl)
PL (1)	PL361307A1 (pl)
WO (1)	WO2001064234A1 (pl)
ZA (1)	ZA200206842B (pl)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003018606A2 (en) *	2001-08-30	2003-03-06	Chay 13 Medical Research Group N.V.	Casein derived peptides and uses thereof in therapy
AU2003217337A1 (en) *	2002-02-06	2003-09-02	University Of North Carolina At Chapel Hill	High-throughput cell identification and isolation method and apparatus
EP1359157A1 (en) *	2002-04-29	2003-11-05	Société des Produits Nestlé S.A.	Metallo-proteinase inhibitory agent
AU2003299568B2 (en) *	2002-11-27	2010-07-22	Ampio Pharmaceuticals, Inc.	Treatment of diseases and conditions mediated by increased phosphorylation
GB0313892D0 (en) *	2003-06-16	2003-07-23	Hannah Res Inst	Control of lactation
WO2005081628A2 (en) *	2004-03-01	2005-09-09	Peptera Pharmaceutical Ltd.	Casein derived peptides and therapeutic uses thereof
BRPI0509541A (pt)	2004-03-30	2007-09-18	Monsanto Technology Llc	métodos para controlar agentes patógenos de planta utilizando n-fosfonometilglicina
WO2005099724A2 (en) *	2004-04-13	2005-10-27	Parallel Solutions, Inc.	Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
WO2007011385A2 (en)	2004-09-28	2007-01-25	Atrium Medical Corporation	Heat cured gel and method of making
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US9012506B2 (en)	2004-09-28	2015-04-21	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
GB0423352D0 (en) *	2004-10-21	2004-11-24	Hannah Res Inst	"Control of mammary cell number"
AU2006242842B2 (en) *	2005-05-02	2011-12-08	Mileutis Ltd.	Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
ES2319475B1 (es) *	2005-06-08	2010-02-16	Consejo Superior Investig. Cientificas	Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US11266607B2 (en) *	2005-08-15	2022-03-08	AbbVie Pharmaceuticals GmbH	Process for the manufacture and use of pancreatin micropellet cores
US9278161B2 (en)	2005-09-28	2016-03-08	Atrium Medical Corporation	Tissue-separating fatty acid adhesion barrier
US9427423B2 (en)	2009-03-10	2016-08-30	Atrium Medical Corporation	Fatty-acid based particles
WO2008040111A1 (en) *	2006-10-04	2008-04-10	Inimex Pharmaceuticals Inc.	Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
KR101410685B1 (ko)	2005-10-04	2014-06-24	솔리제닉스, 인크.	선천적 면역을 조절함으로써 감염을 치료 및 예방하는 것을 포함하는, 면역 관련 장애를 치료 및 예방하기 위한 신규한 펩티드
US20070086958A1 (en) *	2005-10-14	2007-04-19	Medafor, Incorporated	Formation of medically useful gels comprising microporous particles and methods of use
GB2436328A (en) *	2006-03-22	2007-09-26	Regen Therapeutics Plc	Peptide derived from colostrinin
AU2007229603A1 (en) *	2006-03-24	2007-10-04	Unilever Plc	Healthy food product
EP1836906B1 (en) *	2006-03-24	2009-07-01	Unilever N.V.	Healthy food product
EP2124522B1 (en) *	2007-02-05	2011-11-16	National University of Singapore	Putative cytokinin receptor and methods for use thereof
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
EP2255780A1 (en) *	2008-03-12	2010-12-01	Shiseido Company, Ltd.	Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same
KR101355695B1 (ko) *	2009-02-06	2014-01-27	더 프록터 앤드 갬블 캄파니	붕괴성 수분-함유 캡슐
EP2416650B1 (en) *	2009-04-10	2020-02-26	Abraxis BioScience, LLC	Nanoparticle formulations and uses therof
AU2010246067B2 (en)	2009-05-04	2016-07-07	Eyepoint Pharmaceuticals Us, Inc.	Porous silicon drug-eluting particles
US10555527B2 (en) *	2009-05-18	2020-02-11	Monsanto Technology Llc	Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en)	2009-07-17	2009-08-26	Reckitt Benckiser Healthcare I	Skincare compositions
US20110038910A1 (en)	2009-08-11	2011-02-17	Atrium Medical Corporation	Anti-infective antimicrobial-containing biomaterials
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
US11000711B2 (en) *	2009-12-29	2021-05-11	W. R. Grace & Co.-Conn.	Compositions for forming films having a desired degree of obscuration and methods of making and using the same
CN102781404B (zh) *	2010-02-04	2014-08-27	Isp投资公司	用于无水遮光剂配制物的自适应聚合物
EP2536267B1 (en) *	2010-02-18	2015-07-22	Athenix Corp.	AXMI221z, AXMI222z, AXMI223z, AXMI224z, AND AXMI225z DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE
MX2012009634A (es) *	2010-02-18	2012-09-28	Athenix Corp	Genes delta-endotoxinicos axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, y axmi231 y metodos para sus uso.
PE20130649A1 (es)	2010-03-08	2013-07-13	Monsanto Technology Llc	Moleculas polinucleotidicas para regulacion genetica en plantas
FR2958155B1 (fr) *	2010-04-02	2012-04-20	Oreal	Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras
WO2011137563A1 (en)	2010-05-07	2011-11-10	Unilever Plc	High solvent content emulsions
EA033088B1 (ru)	2010-06-04	2019-08-30	Монсанто Текнолоджи Ллс	Трансгенное событие mon 88302 у вида brassica и способы его применения
EP2593141B1 (en)	2010-07-16	2018-07-04	Atrium Medical Corporation	Composition and methods for altering the rate of hydrolysis of cured oil-based materials
WO2012024176A2 (en) *	2010-08-19	2012-02-23	Pioneer Hi-Bred International, Inc.	Novel bacillus thuringiensis gene with lepidopteran activity
US9757374B2 (en)	2010-10-28	2017-09-12	Aequus Pharmaceuticals Inc.	Aripiprazole compositions and methods for its transdermal delivery
BR112013010190B1 (pt) *	2010-10-28	2019-12-31	Aequus Pharmaceuticals Inc	composição farmacêutica
RU2640918C2 (ru)	2010-11-01	2018-01-12	Псивида Юэс, Инк.	Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов
CA2836911A1 (en) *	2011-06-04	2012-12-13	Ian S. CURTIS	Potato transformation compositions, systems, methods, microorganisms, and plants
US20140215655A1 (en) *	2011-08-12	2014-07-31	Bayer Cropscience Nv	Guard cell-specific expression of transgenes in cotton
US10829828B2 (en)	2011-09-13	2020-11-10	Monsanto Technology Llc	Methods and compositions for weed control
US9840715B1 (en)	2011-09-13	2017-12-12	Monsanto Technology Llc	Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10760086B2 (en)	2011-09-13	2020-09-01	Monsanto Technology Llc	Methods and compositions for weed control
CN103957697B (zh)	2011-09-13	2017-10-24	孟山都技术公司	用于杂草控制的方法和组合物
WO2013040116A1 (en)	2011-09-13	2013-03-21	Monsanto Technology Llc	Methods and compositions for weed control
MX343072B (es)	2011-09-13	2016-10-21	Monsanto Technology Llc	Metodos y composiciones para controlar malezas.
EP2755466A4 (en)	2011-09-13	2015-04-15	Monsanto Technology Llc	METHOD AND COMPOSITIONS FOR WEED CONTROL
US10806146B2 (en)	2011-09-13	2020-10-20	Monsanto Technology Llc	Methods and compositions for weed control
US9920326B1 (en)	2011-09-14	2018-03-20	Monsanto Technology Llc	Methods and compositions for increasing invertase activity in plants
JP6188030B2 (ja) *	2011-10-05	2017-08-30	エフエムシーコーポレーションＦｍｃＣｏｒｐｏｒａｔｉｏｎ	微結晶セルロースおよびカルボキシメチルセルロースの安定化剤組成物、該組成物の製造方法並びに食品製品
US9492363B1 (en) *	2012-01-16	2016-11-15	American Spraytech, L.L.C.	Aerosol sprayable color composition
HK1204287A1 (en) *	2012-01-27	2015-11-13	敏捷治疗公司	Transdermal hormone delivery
FR2988566B1 (fr) *	2012-03-28	2014-08-08	Yoplait France	Compositions alimentaires pour stimuler la formation de tissu osseux
US10240162B2 (en)	2012-05-24	2019-03-26	A.B. Seeds Ltd.	Compositions and methods for silencing gene expression
DK2879715T3 (da) *	2012-08-03	2023-04-24	Msm Innovations Inc	Fremgangsmåde og kit til tarmpræparering
US10752949B2 (en)	2012-08-14	2020-08-25	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9701998B2 (en)	2012-12-14	2017-07-11	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9951386B2 (en)	2014-06-26	2018-04-24	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10273541B2 (en)	2012-08-14	2019-04-30	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10221442B2 (en)	2012-08-14	2019-03-05	10X Genomics, Inc.	Compositions and methods for sample processing
JP6367196B2 (ja)	2012-08-14	2018-08-01	テンエックス・ジェノミクス・インコーポレイテッド	マイクロカプセル組成物および方法
US11591637B2 (en)	2012-08-14	2023-02-28	10X Genomics, Inc.	Compositions and methods for sample processing
US10323279B2 (en)	2012-08-14	2019-06-18	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10584381B2 (en)	2012-08-14	2020-03-10	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9617297B2 (en) *	2012-10-11	2017-04-11	The Regents Of The University Of California	Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
AR093058A1 (es)	2012-10-18	2015-05-13	Monsanto Technology Llc	Metodos y composiciones para el control de pestes en plantas
US10533221B2 (en)	2012-12-14	2020-01-14	10X Genomics, Inc.	Methods and systems for processing polynucleotides
EP3567116A1 (en)	2012-12-14	2019-11-13	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9206436B2 (en) *	2012-12-20	2015-12-08	Ut-Battelle, Llc	Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
US10683505B2 (en)	2013-01-01	2020-06-16	Monsanto Technology Llc	Methods of introducing dsRNA to plant seeds for modulating gene expression
UA118841C2 (uk)	2013-01-01	2019-03-25	Ей.Бі. СІДС ЛТД.	Спосіб формування рослини, яка має підвищену стійкість до комахи-шкідника
US10000767B2 (en)	2013-01-28	2018-06-19	Monsanto Technology Llc	Methods and compositions for plant pest control
KR102190198B1 (ko)	2013-02-08	2020-12-14	10엑스 제노믹스, 인크.	폴리뉴클레오티드 바코드 생성
US8961680B2 (en) *	2013-03-08	2015-02-24	Tbf Environmental Technology Inc.	Solvent formulations
US20140271764A1 (en) *	2013-03-12	2014-09-18	Psivida Us, Inc.	Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
EP2967082A4 (en)	2013-03-13	2016-11-02	Monsanto Technology Llc	METHOD AND COMPOSITIONS FOR WEED CONTROL
WO2014164761A1 (en)	2013-03-13	2014-10-09	Monsanto Technology Llc	Methods and compositions for weed control
US20140283211A1 (en)	2013-03-14	2014-09-18	Monsanto Technology Llc	Methods and Compositions for Plant Pest Control
US9352020B2 (en)	2013-03-15	2016-05-31	Mead Johnson Nutrition Company	Reducing proinflammatory response
US9345727B2 (en)	2013-03-15	2016-05-24	Mead Johnson Nutrition Company	Nutritional compositions containing a peptide component and uses thereof
US9289461B2 (en) *	2013-03-15	2016-03-22	Mead Johnson Nutrition Company	Reducing the risk of autoimmune disease
US8889633B2 (en)	2013-03-15	2014-11-18	Mead Johnson Nutrition Company	Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US20140275267A1 (en) *	2013-03-15	2014-09-18	Maria Beug-Deeb Inc. Dba T&M Associates	Methods and compositions for cleaning and disinfecting surfaces
US9345741B2 (en)	2013-03-15	2016-05-24	Mead Johnson Nutrition Company	Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9138455B2 (en)	2013-03-15	2015-09-22	Mead Johnson Nutrition Company	Activating adiponectin by casein hydrolysate
EP2968571A4 (en)	2013-03-15	2016-09-07	Psivida Inc	BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
US10568328B2 (en)	2013-03-15	2020-02-25	Monsanto Technology Llc	Methods and compositions for weed control
CA2817728A1 (en) *	2013-05-31	2014-11-30	Pharmascience Inc.	Abuse deterrent immediate release formulation
JP6668236B2 (ja)	2013-07-19	2020-03-18	モンサントテクノロジーエルエルシー	Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
US9850496B2 (en)	2013-07-19	2017-12-26	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
RS63570B1 (sr) *	2013-10-07	2022-10-31	Bristol Myers Squibb Holdings Ireland	Formulacija atazanavira i kobicistata za lečenje hiv-a
MX390055B (es)	2013-11-04	2025-03-20	Monsanto Technology Llc	Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos.
UA119253C2 (uk)	2013-12-10	2019-05-27	Біолоджикс, Інк.	Спосіб боротьби із вірусом у кліща varroa та у бджіл
CN105979770B (zh)	2014-01-15	2019-07-05	孟山都技术公司	用于使用epsps多核苷酸的杂草控制的方法和组合物
ES2544153B1 (es) *	2014-02-24	2016-06-06	Ntd Labs, S.L.	Uso de un hidrolizado de caseína como agente antiviral
BR112016022711A2 (pt)	2014-04-01	2017-10-31	Monsanto Technology Llc	composições e métodos para controle de pragas de inseto
CA2943624A1 (en)	2014-04-10	2015-10-15	10X Genomics, Inc.	Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
WO2015200223A1 (en)	2014-06-23	2015-12-30	Monsanto Technology Llc	Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en)	2014-06-25	2023-11-07	Monsanto Technology Llc	Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
EP4574974A3 (en)	2014-06-26	2025-10-08	10x Genomics, Inc.	Methods of analyzing nucleic acids from individual cells or cell populations
WO2015200869A1 (en)	2014-06-26	2015-12-30	10X Genomics, Inc.	Analysis of nucleic acid sequences
US12312640B2 (en)	2014-06-26	2025-05-27	10X Genomics, Inc.	Analysis of nucleic acid sequences
US20160008410A1 (en)	2014-07-08	2016-01-14	Mimedx Group, Inc.	Micronized wharton's jelly
US20160022604A1 (en) *	2014-07-23	2016-01-28	Cadila Healthcare Limited	Directly compressed ospemifene compositions
AU2015296700B2 (en)	2014-07-29	2021-10-21	Monsanto Technology Llc	Compositions and methods for controlling insect pests
DK3191083T3 (da) *	2014-09-11	2021-04-19	Gelita Ag	Gelatine-/pektinpartikler
EP3193613A1 (en) *	2014-09-17	2017-07-26	Lonza Inc.	Activated disinfectant hydrogen peroxide compositions
WO2016069939A1 (en)	2014-10-29	2016-05-06	10X Genomics, Inc.	Methods and compositions for targeted nucleic acid sequencing
US9975122B2 (en)	2014-11-05	2018-05-22	10X Genomics, Inc.	Instrument systems for integrated sample processing
TWI713485B (zh) *	2015-01-06	2020-12-21	山田修	利用燃燒合成材料之醫藥組成物、血液處理裝置、化妝品及飲食品
CN107427808B (zh)	2015-01-12	2020-10-23	10X基因组学有限公司	用于制备核酸测序文库的方法和系统以及用其制备的文库
US10968449B2 (en)	2015-01-22	2021-04-06	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
CN107532202A (zh)	2015-02-24	2018-01-02	10X 基因组学有限公司	用于靶向核酸序列覆盖的方法
EP3262407B1 (en)	2015-02-24	2023-08-30	10X Genomics, Inc.	Partition processing methods and systems
MX2017010934A (es)	2015-02-25	2018-01-23	Procter & Gamble	Estructuras fibrosas que comprenden una composicion suavizante de superficies.
US20160303043A1 (en) *	2015-04-16	2016-10-20	Kate Somerville Skincare, LLC	Self-foaming compositions and methods
US10883103B2 (en)	2015-06-02	2021-01-05	Monsanto Technology Llc	Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (en)	2015-06-03	2019-04-24	Monsanto Technology LLC	METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS
EP3320143B1 (en)	2015-07-10	2019-11-13	The Procter and Gamble Company	Fabric care composition comprising metathesized unsaturated polyol esters
SG10202108763UA (en)	2015-12-04	2021-09-29	10X Genomics Inc	Methods and compositions for nucleic acid analysis
WO2017197343A2 (en)	2016-05-12	2017-11-16	10X Genomics, Inc.	Microfluidic on-chip filters
WO2017197338A1 (en)	2016-05-13	2017-11-16	10X Genomics, Inc.	Microfluidic systems and methods of use
EP3481366B1 (en)	2016-07-08	2022-07-27	The Gillette Company LLC	Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters
DE102016223333A1 (de) *	2016-11-24	2018-05-24	Henkel Ag & Co. Kgaa	Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer
US10550429B2 (en)	2016-12-22	2020-02-04	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10815525B2 (en)	2016-12-22	2020-10-27	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10011872B1 (en)	2016-12-22	2018-07-03	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US12264411B2 (en)	2017-01-30	2025-04-01	10X Genomics, Inc.	Methods and systems for analysis
EP4310183B1 (en)	2017-01-30	2025-07-09	10X Genomics, Inc.	Methods and systems for droplet-based single cell barcoding
EP3977985B1 (en) *	2017-03-01	2023-09-06	Arena Pharmaceuticals, Inc.	Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US10398670B2 (en) *	2017-04-24	2019-09-03	Knoze Jr. Corporation	Oral microbiota promotion for oral and/or sinus infections
CN109526228B (zh)	2017-05-26	2022-11-25	10X基因组学有限公司	转座酶可接近性染色质的单细胞分析
US10844372B2 (en)	2017-05-26	2020-11-24	10X Genomics, Inc.	Single cell analysis of transposase accessible chromatin
US10471033B2 (en) *	2017-09-15	2019-11-12	Knoze Jr. Corporation	Oral microbiota promotion for immune system associated inflammations
US12151014B2 (en) *	2017-09-18	2024-11-26	Mast Industries (Far East) Limited	Gloss lip balm formulation
CN111051523B (zh)	2017-11-15	2024-03-19	10X基因组学有限公司	功能化凝胶珠
US10829815B2 (en)	2017-11-17	2020-11-10	10X Genomics, Inc.	Methods and systems for associating physical and genetic properties of biological particles
WO2019195166A1 (en)	2018-04-06	2019-10-10	10X Genomics, Inc.	Systems and methods for quality control in single cell processing
JP2022548138A (ja) *	2019-09-16	2022-11-16	キベルディインコーポレイテッド	微生物タンパク質加水分解産物組成物およびその製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3764670A (en) *	1970-10-28	1973-10-09	Ministry Of Agriculture	Polypeptidic anti-biotic substances derived from casein
US3778426A (en) *	1970-12-16	1973-12-11	Research Corp	Therapeutically useful polypeptides
US4636384A (en) *	1982-06-03	1987-01-13	Stolle Research & Development Corporation	Method for treating disorders of the vascular and pulmonary systems
US4959455A (en) *	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
JP2631470B2 (ja) *	1987-05-15	1997-07-16	雪印乳業株式会社	感染防御剤
US5344820A (en) *	1987-05-15	1994-09-06	Snow Brand Milk Products Co., Ltd.	Infection protectant
JP2805490B2 (ja) *	1989-02-07	1998-09-30	雪印乳業株式会社	細菌毒素中和剤
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
FR2686085B1 (fr) *	1992-01-10	1995-08-04	Agronomique Inst Nat Rech	Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
GB9310472D0 (en) *	1993-05-20	1993-07-07	Univ Warwick	Phenylalanine-free protein and dna coding thereof
TW282398B (pl) *	1993-12-22	1996-08-01	Bristol Myers Squibb Co
US5538952A (en) *	1994-05-26	1996-07-23	Abbott Laboratories	Inhibition of infection of mammalian cells by respiratory syncytial virus
US5506209A (en) *	1994-05-26	1996-04-09	Abbott Laboratories	Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5707968A (en) *	1994-05-26	1998-01-13	Abbott Laboratories	Inhibition of attachment of H.influenzae to human cells
US5712250A (en) *	1994-09-16	1998-01-27	Abbott Laboratories	Product for inhibition of human rotavirus infection
KR0140248B1 (ko) *	1995-03-23	1998-06-15	한상기	신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
US5985275A (en) *	1995-04-12	1999-11-16	New York Blood Center	β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6570060B2 (en) *	1995-05-16	2003-05-27	Mclachlan Corran Norman Stuart	Milk lacking β-casein A1
KR100221124B1 (ko) *	1996-09-23	1999-10-01	한상기	신규한 카제인 및 그 제조방법
US5830434A (en) *	1997-02-26	1998-11-03	Medical University Of South Carolina Foundation For Research Development	Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP4191261B2 (ja) *	1997-03-21	2008-12-03	雪印乳業株式会社	鉄カゼイン類分解物複合体及びその製造法
US6358508B1 (en) *	1997-06-11	2002-03-19	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor TR9
ATE256185T1 (de) *	1997-08-29	2003-12-15	Brigham & Womens Hospital	T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
AUPP051497A0 (en) *	1997-11-24	1997-12-18	University Of Melbourne, The	Antimicrobial peptides
US5985575A (en) *	1998-05-20	1999-11-16	Wisconsin Alumni Research Foundation	Tethered function assay for protein function
US6570606B1 (en) *	1998-05-29	2003-05-27	3Com Corporation	Method and apparatus for controlling transmission of media signals over a data network in response to triggering events at participating stations
HK1044040A1 (zh) *	1998-11-16	2002-10-04	德克萨斯州立大学董事会	Hiv-特异的t-细胞诱导
GB9927603D0 (en) *	1999-11-22	2000-01-19	Nestle Sa	Use of a milk protein hydrolysate in the treatment of diabetes
IL138946A0 (en) *	2000-10-11	2001-11-25	Compugen Ltd	Method for the identification of peptides and proteins
EP1928473A4 (en) *	2005-09-28	2009-11-18	Dnp Canada Inc	COMBINATION OF POLYCHITOSAMINE AND FIBRATE FOR THE PREVENTION AND TREATMENT OF HYPERLIPIDEMIA
US8865876B2 (en) *	2008-06-02	2014-10-21	California Institute Of Technology	Engineered lectin oligomers with antiviral activity

2000
- 2000-03-01 IL IL13483000A patent/IL134830A0/xx unknown
2001
- 2001-03-01 NZ NZ521016A patent/NZ521016A/en unknown
- 2001-03-01 CA CA002401550A patent/CA2401550A1/en not_active Abandoned
- 2001-03-01 EA EA200401467A patent/EA007217B1/ru not_active IP Right Cessation
- 2001-03-01 AU AU35962/01A patent/AU782662B2/en not_active Ceased
- 2001-03-01 HU HU0301003A patent/HUP0301003A3/hu unknown
- 2001-03-01 CZ CZ20022915A patent/CZ20022915A3/cs unknown
- 2001-03-01 WO PCT/IL2001/000198 patent/WO2001064234A1/en not_active Ceased
- 2001-03-01 JP JP2001563131A patent/JP2003528827A/ja active Pending
- 2001-03-01 PL PL36130701A patent/PL361307A1/pl unknown
- 2001-03-01 MX MXPA02008569A patent/MXPA02008569A/es not_active Application Discontinuation
- 2001-03-01 DE DE60140794T patent/DE60140794D1/de not_active Expired - Lifetime
- 2001-03-01 DK DK01908105.8T patent/DK1261360T3/da active
- 2001-03-01 BR BR0109027-5A patent/BR0109027A/pt not_active IP Right Cessation
- 2001-03-01 EP EP01908105A patent/EP1261360B1/en not_active Expired - Lifetime
- 2001-03-01 EA EA200200820A patent/EA005579B1/ru not_active IP Right Cessation
- 2001-03-01 AT AT01908105T patent/ATE451929T1/de not_active IP Right Cessation
- 2001-03-01 CN CN01808959A patent/CN1427725A/zh active Pending
- 2001-08-30 US US09/942,121 patent/US20020147144A1/en not_active Abandoned
2002
- 2002-08-19 IL IL151351A patent/IL151351A/en active IP Right Grant
- 2002-08-27 ZA ZA200206842A patent/ZA200206842B/en unknown
- 2002-08-29 EA EA200400376A patent/EA007814B1/ru not_active IP Right Cessation
- 2002-08-30 NO NO20024157A patent/NO20024157L/no not_active Application Discontinuation
- 2002-08-31 KR KR10-2002-7011450A patent/KR20030025907A/ko not_active Ceased
2006
- 2006-09-08 US US11/518,400 patent/US7741274B2/en not_active Expired - Lifetime
2007
- 2007-10-31 US US11/982,369 patent/US20090192081A1/en not_active Abandoned
2010
- 2010-04-22 US US12/764,996 patent/US20100298216A1/en not_active Abandoned
- 2010-07-28 US US12/844,834 patent/US20100317601A1/en not_active Abandoned
2012
- 2012-09-05 US US13/603,428 patent/US8735348B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU782662B2 (en)	2005-08-18
EA007814B1 (ru)	2007-02-27
EP1261360A1 (en)	2002-12-04
NO20024157D0 (no)	2002-08-30
US20100298216A1 (en)	2010-11-25
EA200200820A1 (ru)	2003-08-28
MXPA02008569A (es)	2003-02-24
US20070161557A1 (en)	2007-07-12
CN1427725A (zh)	2003-07-02
US8735348B2 (en)	2014-05-27
EA005579B1 (ru)	2005-04-28
HUP0301003A2 (hu)	2003-07-28
US7741274B2 (en)	2010-06-22
DK1261360T3 (da)	2010-05-03
US20130096073A1 (en)	2013-04-18
BR0109027A (pt)	2003-06-03
ATE451929T1 (de)	2010-01-15
EA200400376A1 (ru)	2005-06-30
EP1261360B1 (en)	2009-12-16
NZ521016A (en)	2005-08-26
EA200401467A1 (ru)	2005-04-28
EP1261360A4 (en)	2004-03-10
NO20024157L (no)	2002-10-30
JP2003528827A (ja)	2003-09-30
IL134830A0 (en)	2001-05-20
CZ20022915A3 (cs)	2003-03-12
US20100317601A1 (en)	2010-12-16
US20090192081A1 (en)	2009-07-30
KR20030025907A (ko)	2003-03-29
AU3596201A (en)	2001-09-12
HUP0301003A3 (en)	2007-08-28
CA2401550A1 (en)	2001-09-07
EA007217B1 (ru)	2006-08-25
ZA200206842B (en)	2003-07-28
IL151351A (en)	2012-04-30
US20020147144A1 (en)	2002-10-10
WO2001064234A1 (en)	2001-09-07
DE60140794D1 (de)	2010-01-28

Legal Events

Date	Code	Title	Description
2009-08-31	DISC	Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
EP1261360A4 (en)	2004-03-10	PEPTIDES DERIVED FROM CASEIN AND THEIR APPLICATION FOR THERAPY
WO2005081628A3 (en)	2007-10-18	Casein derived peptides and therapeutic uses thereof
AU3698697A (en)	1998-02-09	Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
ATE314095T1 (de)	2006-01-15	Virusähnliche partikel zur induktion von autoantikörpern
DE69841982D1 (de)	2010-12-16	Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
PL375113A1 (pl)	2005-11-28	Peptydy pochodzące z kazeiny i ich zastosowania do leczenia
WO2000054813A3 (en)	2001-05-03	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FI971613A7 (fi)	1997-04-16	Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
TR200102308T2 (tr)	2002-04-22	Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
NZ511020A (en)	2003-06-30	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
NZ707292A (en)	2017-06-30	Activin-actrii antagonists and uses for increasing red blood cell levels
NZ505834A (en)	2002-12-20	Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
IL141984A0 (en)	2002-03-10	Akt nucleic acids, polypeptides, and uses thereof
NZ508505A (en)	2003-04-29	Treatment of wounds using an Egr-1 transcription factor polypeptide
NO971247L (no)	1997-03-18	Defektive, rekombinante adenoviruser med inaktivt IVa2-gen
WO2001045738A3 (en)	2001-12-27	Use of heat shock proteins to enhance production of chemokines by a cell
JPS6455182A (en)	1989-03-02	Human papilloma virus of type 41, dna thereof and protein coded thereby
AU5489500A (en)	2001-01-02	Isolation of a human retrovirus
WO2001004318A3 (en)	2001-08-09	Myxoma virus genes for immune modulation
DE3769497D1 (de)	1991-05-29	Mittel zur bekaempfung von phytopathogenen mikroben.
MXPA05007901A (es)	2005-09-21	Terapia de combinacion para hcv.
MD2053C2 (ro)	2003-07-31	Remediu cu acţiune interferonogenă
DK1250422T3 (da)	2006-05-29	Myeloid-kolonistimulerende faktor og anvendelser deraf
WO2001087333A3 (de)	2002-05-16	Mittel zur stimulation des immunsystems
WO2000024876A3 (en)	2000-11-02	Spumavirus isolated from humans